Eloralintide and Tirzepatide + Eloralintide
Phase 1Completed 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Overweight
Conditions
Overweight, Obesity
Trial Timeline
Apr 9, 2025 → Jan 19, 2026
NCT ID
NCT06916065About Eloralintide and Tirzepatide + Eloralintide
Eloralintide and Tirzepatide + Eloralintide is a phase 1 stage product being developed by Eli Lilly for Overweight. The current trial status is completed. This product is registered under clinical trial identifier NCT06916065. Target conditions include Overweight, Obesity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06916065 | Phase 1 | Completed |
Competing Products
20 competing products in Overweight
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TERN-601 | Terns Pharmaceuticals | Phase 2 | 49 |
| LY3457263 + Tirzepatide + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3305677 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3537031 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Lisdexamfetamine Dimesylate + Placebo (oral) + Placebo (injection) | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY4064912 + LY4064912 + Placebo + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3437943 + Ethinyl Estradiol + Drospirenone | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Acetaminophen | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 2 | 52 |
| Eloralintide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3437943 + Placebo | Eli Lilly | Phase 1 | 33 |
| LY3502970 + Placebo | Eli Lilly | Phase 1 | 33 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| Tirzepatide + Placebo | Eli Lilly | Phase 3 | 77 |
| LY3541105 + Placebo | Eli Lilly | Phase 1 | 33 |
| Retatrutide + Placebo | Eli Lilly | Phase 2 | 52 |
| LY4167586 + Placebo + LY4167586 | Eli Lilly | Phase 1 | 33 |
| AZD9550 + AZD6234 + Placebo comparator | AstraZeneca | Phase 2 | 52 |
| pramlintide acetate + sibutramine + phentermine + placebo | AstraZeneca | Phase 2 | 52 |